These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6134517)

  • 21. [Beta-endorphin concentration in the cerebrospinal fluid of schizophrenics].
    Ignatov SA; Burbaeva GSh; Tsutsul'kovskaia MIa; Abramova LI; Trubnikov VI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(9):1331-7. PubMed ID: 6108032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenylacetic acid excretion in schizophrenia and depression: the origins of PAA in man.
    Karoum F; Potkin S; Chuang LW; Murphy DL; Liebowitz MR; Wyatt RJ
    Biol Psychiatry; 1984 Feb; 19(2):165-78. PubMed ID: 6713036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low angiotensin-converting enzyme activity (kininase II) in cerebrospinal fluid of schizophrenics.
    Beckmann H; Saavedra JM; Gattaz WF
    Biol Psychiatry; 1984 May; 19(5):679-84. PubMed ID: 6145452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls.
    Gattaz WF; Gasser T; Beckmann H
    Biol Psychiatry; 1985 Apr; 20(4):360-6. PubMed ID: 2858227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls.
    Beckmann H; Lang RE; Gattaz WF
    Psychoneuroendocrinology; 1985; 10(2):187-91. PubMed ID: 4034849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication.
    Glovinsky D; Kalogeras KT; Kirch DG; Suddath R; Wyatt RJ
    Schizophr Res; 1994 Feb; 11(3):273-6. PubMed ID: 7910756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melatonin immunoreactivity in cerebrospinal fluid of schizophrenic patients and healthy controls.
    Beckmann H; Wetterberg L; Gattaz WF
    Psychiatry Res; 1984 Feb; 11(2):107-10. PubMed ID: 6143334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls.
    Beckmann H; Gattaz WF
    J Neural Transm (Vienna); 2002 May; 109(5-6):931-8. PubMed ID: 12111479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history.
    Lindström LH
    Psychiatry Res; 1985 Apr; 14(4):265-73. PubMed ID: 2410940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic treatment.
    Sharma RP; Bissette G; Janicak P; Davis JM; Nemeroff CB
    Schizophr Res; 1994 Sep; 13(2):173-7. PubMed ID: 7986775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Tolerance" to neuroleptic-induced CSF HVA rise in schizophrenic patients in relation to clinical response.
    Joseph MH; Waddington JL
    Psychiatry Res; 1982 Aug; 7(1):133. PubMed ID: 6127745
    [No Abstract]   [Full Text] [Related]  

  • 33. Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values.
    Sandler M; Ruthven CR; Goodwin BL; Lees A; Stern GM
    J Neurol Neurosurg Psychiatry; 1982 Apr; 45(4):366-8. PubMed ID: 7077347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with increased noradrenaline levels in schizophrenic patients.
    Kemali D; Maj M; Galderisi S; Grazia Ariano M; Starace F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):49-59. PubMed ID: 2300679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precursors and metabolites of phenylethylamine, m and p-tyramine and tryptamine in human lumbar and cisternal cerebrospinal fluid.
    Young SN; Davis BA; Gauthier S
    J Neurol Neurosurg Psychiatry; 1982 Jul; 45(7):633-9. PubMed ID: 6181210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients.
    Heikkilä L; Rimón R; Terenius L
    Psychiatry Res; 1990 Dec; 34(3):229-36. PubMed ID: 1706098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
    Beinfeld MC; Garver DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):601-9. PubMed ID: 1956989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenylethylamine excretion in depression.
    DeLisi LE; Murphy DL; Karoum F; Mueller E; Targum S; Wyatt RJ
    Psychiatry Res; 1984 Nov; 13(3):193-201. PubMed ID: 6597458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.
    Kirstein L; Bowers MB; Heninger G
    Biol Psychiatry; 1976 Aug; 11(4):421-34. PubMed ID: 963133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.